Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: Spago Nanomedical publishes positive preclinical data

Spago Nanomedical

Preclinical data with Spago Nanomedical's radionuclide therapy concept Tumorad was recently published in the scientific journal ACS Omega. The paper describes the composition, stability and mode of action for the drug candidate [177]Lu-SN201 and concludes that the candidate's properties are suitable for systemic treatment of cancer. BioStock reached out to CEO Mats Hansen to learn more on what this means for the project.

Read the full interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2023/01/spago-nanomedical-publishes-positive-preclinical-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.